NCT00565474View on ClinicalTrials.gov

Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant

PHASE4CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

September 30, 2001

Primary Completion Date

October 31, 2007

Conditions
Graft Vasculopathy
Interventions
DRUG

Fluvastatin

Graft vasculopathy

Trial Locations (1)

Unknown

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT00565474 - Evaluation of the Effect of Fluvastatin 40 mg (b.i.d.) in the Prevention of the Development of Vasculopathy of the Graft in de Novo Renal Transplant Patients Transplant | Biotech Hunter | Biotech Hunter